Top Markets
#1 B3 (Base) B3 (Base) +17.71%
#2 Siacoin Siacoin +14.92%
#3 BORA BORA +4.81%
#4 The Black Bull The Black Bull +4.53%
#5 MVL MVL +4.32%
#6 TROLL TROLL +4.30%
#7 Kaia Kaia +4.24%
#8 OriginTrail OriginTrail +3.41%
#9 Stratis Stratis +3.39%
#10 Power Ledger Power Ledger +3.13%
Coin of the day
B3 (Base) B3 (Base)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Energenesis Biomedical CO.,LTD. Energenesis Biomedical CO.,LTD.

Energenesis Biomedical CO.,LTD.

6657
Rangering i aksjer #22642
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered... Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
Aksjekurs
$0.97305026
Sist synkronisert: 2026-08-21
Markedsverdi
$85.54M
Endring (1 dag)
1.16%
Endring (1 år)
-50.40%
Land
TW
Handel Energenesis Biomedical CO.,LTD. (6657)

Kategori

Healthcare
P/E-forhold for Energenesis Biomedical CO.,LTD. (6657)
P/E-forhold per 2026 TTM: 0
Ifølge Energenesis Biomedical CO.,LTD. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Energenesis Biomedical CO.,LTD. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.